Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - February 10, 2023 Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
Clinical Impact of Additional Cilostazol Treatment on Restenosis Risk following Heparin-Bonded Stent Graft Implantation: Sub-Analysis from the Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study
CONCLUSIONS: Our study revealed the clinical impact of additional cilostazol treatment on the risk of restenosis and acute thrombotic occlusion following heparin-bonded stent graft implantation, while TLR and surgical reconstruction were not significantly different.PMID:36725018 | DOI:10.5551/jat.63874 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - February 1, 2023 Category: Cardiology Authors: Kazuki Tobita Mitsuyoshi Takahara Osamu Iida Yoshimitsu Soga Terutoshi Yamaoka Shigeo Ichihashi Shigeru Saito Source Type: research
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention
(Source: Neurocritical Care)
Source: Neurocritical Care - February 1, 2023 Category: Neurology Source Type: research
Combined carvacrol and cilostazol ameliorate ethanol-induced liver fibrosis in rats: Possible role of SIRT1/Nrf2/HO-1 pathway
Int Immunopharmacol. 2023 Jan 27;116:109750. doi: 10.1016/j.intimp.2023.109750. Online ahead of print.ABSTRACTCarvacrol is a natural phenolic monoterpenoid, and cilostazol is a selective phosphodiesterase-3 inhibitor with antioxidant, anti-inflammatory and antiapoptotic effects. This experiment aimed to explore the hepatoprotective effects of carvacrol and cilostazol alone and in combination against alcoholic liver fibrosis (ALF), and the underlying mechanisms, using silymarin as a reference anti-fibrotic product. ALF was induced by oral administration of ethanol (1 ml/100 g/day) thrice per week. Silymarin (100 mg/kg), car...
Source: International Immunopharmacology - January 29, 2023 Category: Allergy & Immunology Authors: Sally E Abu-Risha Samia S Sokar Heba R Elbohoty Alaa E Elsisi Source Type: research
Combined carvacrol and cilostazol ameliorate ethanol-induced liver fibrosis in rats: Possible role of SIRT1/Nrf2/HO-1 pathway
Int Immunopharmacol. 2023 Jan 27;116:109750. doi: 10.1016/j.intimp.2023.109750. Online ahead of print.ABSTRACTCarvacrol is a natural phenolic monoterpenoid, and cilostazol is a selective phosphodiesterase-3 inhibitor with antioxidant, anti-inflammatory and antiapoptotic effects. This experiment aimed to explore the hepatoprotective effects of carvacrol and cilostazol alone and in combination against alcoholic liver fibrosis (ALF), and the underlying mechanisms, using silymarin as a reference anti-fibrotic product. ALF was induced by oral administration of ethanol (1 ml/100 g/day) thrice per week. Silymarin (100 mg/kg), car...
Source: International Immunopharmacology - January 29, 2023 Category: Allergy & Immunology Authors: Sally E Abu-Risha Samia S Sokar Heba R Elbohoty Alaa E Elsisi Source Type: research
Antithrombotic treatment after stroke due to intracerebral haemorrhage
CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic...
Source: Cochrane Database of Systematic Reviews - January 26, 2023 Category: General Medicine Authors: Alexia Cochrane Chen Chen Jacqueline Stephen Ole Morten R ønning Craig S Anderson Graeme J Hankey Rustam Al-Shahi Salman Source Type: research
Antithrombotic treatment after stroke due to intracerebral haemorrhage
CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic...
Source: Cochrane Database of Systematic Reviews - January 26, 2023 Category: General Medicine Authors: Alexia Cochrane Chen Chen Jacqueline Stephen Ole Morten R ønning Craig S Anderson Graeme J Hankey Rustam Al-Shahi Salman Source Type: research
